A Phase 2 interventional study of alagebrium chloride (ALT-711) in Hypertension, sponsored by Synvista Therapeutics, Inc. Terminated at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-02-08.
Sponsored by Synvista Therapeutics, Inc · Phase 2, Interventional, and Treatment
This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 392 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Synvista Therapeutics, Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This study is terminated, as verified in Jun 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Synvista Therapeutics, Inc